PR Newswire All News ReleasesCodex · 实盘不做把握 7/10不做原因:无增量信息
北京时间·🕒 发布 16:03:00·⟳ 抓取 16:03:24 +24s·⚡ 决策 08-27 16:19:15 +15m51s·61.2 天前
DJS律所再次征集Capricor证券集体诉讼投资者
本次PR Newswire内容不是FDA新决定、法院新进展或公司新披露，而是律所对既有证券诉讼的重复征集；在缺少新增事实和真实报价校验的情况下不生成交易单。
📄 原文PR Newswire All News Releases↗ 原文
Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAP…
不做 Capricor Therapeutics, Inc.（CAPR.US）
不做Capricor Therapeutics, Inc.（CAPR.US）：本条是律所重复诉讼征集，核心FDA统计分析争议和诉讼事项已提前数周公开且已触发大幅重定价；同时未取得真实报价和事件研究校验，不能生成可执行SHORT。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Capricor的实质负面催化是2026-07-27 FDA简报披露Deramiocel统计分析计划问题及随后诉讼启动，市场此前已按该信息重定价；2026-08-27 DJS公告仅重复诉讼指控和索赔期，未新增FDA、法院、赔偿金额或业务进展，因此对CAPR.US没有新的可交易边际。
消息传播链
- 多家律所材料称FDA在2026-07-27盘前发布Deramiocel顾问委员会简报，指出统计分析计划变更未在BLA提交前获FDA讨论和同意；未在本环境直接命中FDA原文。市场反应:BFA材料称CAPR从2026-07-24收盘19.70美元跌至2026-07-27的7.00美元，跌幅约64.5%。
- Capricor披露FDA细胞、组织和基因治疗顾问委员会以3票赞成、9票反对认为现有证据不支持Deramiocel治疗DMD心肌病有效性。
- BFA Law已发布同类证券集体诉讼提醒，重复统计分析计划和FDA未同意的核心指控。
- DJS Law Group再次提醒投资者参与同一索赔期和同一Deramiocel统计分析计划争议相关的证券集体诉讼。市场反应:事件抓取时为美股盘前，未取得真实盘前报价。
关键理由
- 律所提醒类新闻通常是既有集体诉讼的投资者征集，不等同于新的监管处罚或法院裁定。
- 公开资料显示同一Deramiocel统计分析计划争议和诉讼提醒已在2026年7月底至8月上旬出现，本条缺少新增基本面信息。
主要风险
- 若后续出现FDA正式拒批、法院实质性进展或公司披露潜在赔付金额，CAPR.US仍可能出现新的下行催化。
- 未能调用stock_tools核验当前报价、案例库和事件研究，交易执行边界不可定。
反向证据
- 做空前查反向 · 来源 web · 日期 2026-08-10 · 影响 weakens
核心负面事实已由FDA简报、公司8-K和多家律所公告提前传播，本条DJS提醒不构成新的强空催化。
检索:Capricor Deramiocel FDA advisory committee July 2026 class action already reported 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足未用于设定交易价格；最终回避主要由无新增事实和无法核验行情决定。
方向:未完成合规event_study；从事件机制看，律所重复征集本身通常不构成新的强空催化。
涨幅量级:没有可用高相似、同市场、锚点干净的先例用于校准幅度。
形态:证券诉讼提醒类公告常跟随此前股价暴跌和监管/临床负面事实，单独公告的新增定价力弱。
原文全文
展开原文 · 2,208 字
Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR
LOS ANGELES, Aug. 27, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of CAPR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: December 17, 2025 to July 26, 2026
DEADLINE: September 28, 2026
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Capricor modified the statistical analysis plan used in the analysis of clinical data for Deramiocel. The Company failed to secure the FDA's agreement to this change before it resubmitted a Biologics License Application for the drug. Based on these facts, Capricor's public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. As one of the founding partners of Schall Brown & Schwartz LLP (schallfirm.com), David Schwartz specializes in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]
SOURCE DJS Law Group LLP
LOS ANGELES, Aug. 27, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of CAPR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: December 17, 2025 to July 26, 2026
DEADLINE: September 28, 2026
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Capricor modified the statistical analysis plan used in the analysis of clinical data for Deramiocel. The Company failed to secure the FDA's agreement to this change before it resubmitted a Biologics License Application for the drug. Based on these facts, Capricor's public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. As one of the founding partners of Schall Brown & Schwartz LLP (schallfirm.com), David Schwartz specializes in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]
SOURCE DJS Law Group LLP
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。